Biomarkers that Can Predict Resistance to Radiation Therapy Identified in HNSCC

Article

The effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck has been reviewed by an international team of researchers. They identified two biomarkers that were good at predicting a patient's resistance to radiation therapy. "While our findings are encouraging, and a step toward personalized medicine, we hope to do more of this research with a larger, randomized trial," the authors conclude.

An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck. They identified two markers that were good at predicting a patient's resistance to radiation therapy. Their findings were published in the February issue of the European Journal of Cancer.

Explains Dr. Akervall, co-director, Head and Neck Cancer Multidisciplinary Clinic, Beaumont Hospital, Royal Oak, and clinical director of Beaumont's BioBank, "Radiation therapy is a common treatment for people with squamous cell cancer of the head and neck. However, it's not always well-tolerated. It can take two months, resulting in lots of side effects. Some of these complications are permanent. Before my patient goes down that path, I really want to know if their tumors are going to respond to radiation. That's where the patient's biomarkers can shed some light. If not, we can look at other treatment options -- saving time, possible risk for complications and expense."

Read the complete story here: http://bit.ly/O4YhY0

Source: ScienceDaily

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.